

RECEIVED  
CENTRAL FAX CENTER

DEC 22 2006

PATENT

Attorney Docket No.: 10062.210-US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Thisted et al. Confirmation No: 1994

Serial No.: 10/630,203 Group Art Unit: 1652

Filed: July 29, 2003 Examiner: Prouty

For: Alpha-Amylase Mutants with Altered Properties

**PETITION AND FEE FOR SUSPENSION OF ACTION BY OFFICE**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the Office Action mailed June 30, 2006, Applicants hereby petition the Commissioner for a suspension of action by the Office. The basis for the showing of good and sufficient cause for suspension of action is set forth below:

The Office action of June 30, 2006 contains a rejection of the instant application claims under 35 U.S.C. 102(e) over Applicants' US Patent Publication 2003/0129718. The US Patent Publication and instant application contain a common inventor, and accordingly, the US Patent Publication may not be prior art of "another." Applicants are investigating whether the invention disclosed but not claimed in this cited reference was derived from the common inventor and whether inventorship of the instant application or the cited reference is proper.

Applicants request suspension of action by the Office for a period of two months.

Please charge the required fee under 37 C.F.R. 1.17(g), estimated to be \$200.00, to Novozymes North America, Inc., Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

12/27/2006 HDEMESS1 00000054 501701 10630203

02 FC:1463 200.00 DA

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

  
\_\_\_\_\_  
Jason I. Garbell, Reg. No. 44,116  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212)840-0097

Date: December 22, 2006

RECEIVED  
CENTRAL FAX CENTER

DEC 22 2006

Attorney Docket No.: 10062.210-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Thisted et al. Confirmation No: 1994

Serial No.: 10/630,203 Group Art Unit: 1652

Filed: July 29, 2003 Examiner: Prouty

For: Alpha-Amylase Mutants with Altered Properties

**PETITION AND FEE FOR SUSPENSION OF ACTION BY OFFICE**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the Office Action mailed June 30, 2006, Applicants hereby petition the Commissioner for a suspension of action by the Office. The basis for the showing of good and sufficient cause for suspension of action is set forth below:


The Office action of June 30, 2006 contains a rejection of the instant application claims under 35 U.S.C. 102(e) over Applicants' US Patent Publication 2003/0129718. The US Patent Publication and instant application contain a common inventor, and accordingly, the US Patent Publication may not be prior art of "another." Applicants are investigating whether the invention disclosed but not claimed in this cited reference was derived from the common inventor and whether inventorship of the instant application or the cited reference is proper.

Applicants request suspension of action by the Office for a period of two months.

Please charge the required fee under 37 C.F.R. 1.17(g), estimated to be \$200.00, to Novozymes North America, Inc., Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

  
\_\_\_\_\_  
Jason I. Garbell, Reg. No. 44,116  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212)840-0097

Date: December 22, 2006